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Fractionnement et des Biotechnologies, Les Ulis, 91958 Courtaboeuf Cedex, France
Contributed by Hector F. DeLuca, June 28, 2006
Since the discovery of calbindin D9k, its role in intestinal calcium
absorption has remained unsettled. Further, a wide distribution of
calbindin D9k among tissues has argued for its biological impor-
tance. We discovered a frameshift deletion in the calbindin D9k
gene in an ES cell line, E14.1, that originated from 129OlaHsd mice.
We produced mice with the mutant calbindin D9k gene by injecting
the E14.1 ES cell subline into the C57BL6 host blastocysts and
proved that these mice lack calbindin D9k protein. Calbindin D9k
knockout mice were indistinguishable from wild-type mice in
phenotype, were able to reproduce, and had normal serum calcium
levels. Thus, calbindin D9k is not required for viability, reproduc-
tion, or calcium homeostasis.
vitamin D3  E14ES cells  calcium homeostasis
For decades, a major physiologic function of calbindin D9k wasbelieved to be a carrier of calcium during intestinal calcium
absorption (1). However, the detailed mechanism of vitamin
D-induced intestinal calcium absorption still is not fully under-
stood. According to the currently accepted model, vitamin
D-mediated transcellular calcium absorption in the intestine
proceeds through the calcium channel proteins TRPV5 and
TRPV6 (2) with the involvement of cellular calcium transfer
protein calbindin D9k (1, 3) and a calcium extrusion protein,
calcium ATPase (PMCA1b) (4). The data on regulation of
epithelial calcium channels (TRPV5 and TRPV6), calbindin D9k,
and PMCA1b expression by 1,25-dihydroxyvitamin D3 seem
clear, and these genes have vitamin D responsive elements in
their promoter regions (5–7).
Calbindin D9k was first discovered as the mammalian coun-
terpart to the calbindin D28k that was found in chick duodenal
mucosa in response to vitamin D3 (8, 9). Later, calbindin D9k
from vitamin D3-responsive rat intestinal mucosa was identified,
purified, and characterized (9, 10). Since its discovery in 1967,
the role of calbindin D9k protein in vitamin D3-mediated intes-
tinal calcium absorption has been intensively studied but still
remains unsettled. In the meantime, a wide distribution of this
protein in tissues not involved in calcium absorption has been
noted, arguing for its importance in biology (11–13).
In 1969, Harmeyer and DeLuca (14) provided evidence that
calcium absorption and calbindin D9k levels in response to
vitamin D3 are not directly related. Similar discrepancies were
reported by others (15). Additional doubts concerning the role
of calbindin D9k in calcium transport appeared after studies in
vitamin D receptor knockout mice (16, 17). The absence of a
calbindin D9k-mediated mechanism for active Ca2 transport
was also shown in sheep rumen (18). In our microarray exper-
iments, we demonstrated that expression of the calbindin D9k
gene was only slightly up-regulated by 1,25-dihydroxyvitamin D3
[1,25-(OH)2D3] in the intestine of vitamin D3-deficient rats (19).
We also found that, although administration of some analogs of
1,25-(OH)2D3 stimulated Ca2 absorption in the intestine of
vitamin D-deficient rats, the expression of calbindin D9k was not
changed.
We have now produced a strain of mice lacking the calbindin
D9k protein. This mouse is indistinguishable from the wild type
in phenotype and in serum calcium level, regardless of age or
gender. Additionally, these mice are able to reproduce. Thus,
calbindin D9k is not required for viability, reproduction, or
calcium homeostasis.
Results and Discussion
Discovery of the Mutant Mouse Calbindin D9k Gene. The P1 clone
7681 with an 85-kb insert of genomic DNASauIIIA containing
the mouse calbindin D9k gene was purchased from Incyte
Genomics (Palo Alto, CA). The P1 mouse library was generated
by Sternberg et al. (20) by using genomic DNA from the ES cell
line subclone E14.1, which is derived from E14 ES cells (21). The
ES cell line E14 was derived from the inbred mouse strain
129OlaHsd in 1985 by Hooper et al. (22). The insert was cut
with BamHI and subcloned into pBluescript (Stratagene, La
Jolla, CA). The clone that was positive for the calbindin D9k gene
was selected by Northern blot analysis, and a plasmid with the
mutant calbindin D9k insert was isolated. We have sequenced the
10.409-kb insert containing the calbindin D9k gene and com-
pared it with the 8.434 kb of deposited sequence of the calbindin
D9k gene of mouse strain ICRxSwiss (GenBank accession no.
AY034822). Both sequences overlap in the calbindin D9k gene
region, but our sequence is 2,111 bp downstream of the
AY034822 sequence. Both sequences seemed to be 98–99%
identical, with a few gaps in noncoding regions. The major
difference we discovered in the calbindin D9k gene sequence was
the deletion of 22 nt in exon III compared with AY034822 (Fig.
1). This deletion resulted in a frameshift, thereby creating a new
in-frame stop codon 63 nt downstream of the original stop codon
(Fig. 1), which could generate a hypothetical mutant calbindin
D9k protein that would be 21 aa longer than the native protein.
The deduced mutant protein should be 100 aa long, with a
molecular weight of 11,363 and a theoretical pI of 9.07 with a
total of 14 negatively charged residues (Asp plus Glu) and a total
of 17 positively charged residues (Arg plus Lys). The wild-type
protein is 79 aa, with a molecular weight of 8,970 and a
theoretical pI of 4.69 with a total of 16 negatively charged
residues (Asp plus Glu) and a total of 11 positively charged
residues (Arg plus Lys). We aligned sequences of the wild-type
protein and the deduced mutant calbindin D9k protein (Fig. 2).
Both proteins are identical in the first 51 aa and have no
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similarity after that. Wild-type calbindin D9k protein, as a
Ca2-binding protein, has two EF hands and is acidic (23),
whereas the mutant calbindin D9k is missing the second EF hand
and is basic. We assumed that this protein might not exist in vivo,
as was shown for caspase 3 (24), so mice with this mutant
calbindin D9k gene could potentially be calbindin D9k null.
Generation of Mutant Calbindin D9k Gene Mice. We first checked
whether the original 129OlaHsd mice, which were the source of
the ES cell line E14.1, have the same 22-nt deletion in the
calbindin D9k gene, but they did not. We checked several other
129 mouse substrains, and all of them had the wild-type calbindin
D9k genotype. So the only source of the mutant calbindin D9k
gene was the ES cell subclone E14.1.
We generated mice with the mutant calbindin D9k gene by
injection of the E14.1 ES cell subline into C57BL6 host
blastocysts as described in Materials and Methods. Chimeric
males were bred to 129OlaHsd females to generate an inbred
129OlaHsd line that was homozygous for the mutant calbindin
D9k gene with a 22-nt deletion in exon III as was confirmed by
genotyping.
Mutant Calbindin D9k Mice Have the Knockout Phenotype. Mice
homozygous for the mutant calbindin D9k gene (22 nt deleted in
exon III) were generated and mRNA analyzed by RT-PCR. For
this, we used primers flanking the entire coding region of the
calbindin D9k gene. These primers (see Materials and Methods)
amplified a 418-bp product from wild-type mice and a 396-bp
product from the mutant mice. As expected, no full-length
product (418 bp) was detected in mutant calbindin D9k mice.
Both products were sequenced to confirm the specificity of the
amplification. Sequencing data revealed that the PCR product
obtained from the mRNA of mutant mice had the identical 22-bp
deletion detected in exon III of the mutant calbindin D9k gene.
To determine whether either the mutant or wild-type calbi-
ndin D9k protein could be detected in the mutant mouse
duodenum lysate, we used all available antibodies. Western blot
analysis was carried out by using duodenal lysates from the
wild-type and mutant mice. As shown in Fig. 3A, an antibody
raised against the full-length calbindin D9k protein (1–79 aa)
recognized a 9-kDa band in the wild type; however, neither a
9-kDa band (wild-type protein) nor an 11.3-kDa (mutant pro-
tein) band was detected in the mutant mice duodenal lysates. The
antibody to the common segment (1–60 aa) of both wild-type
and putative mutant calbindin D9k proteins detected the wild-
type protein band but failed to detect either of these bands in the
mutant duodenal lysate (Fig. 3B).
To be sure that the mutant calbindin D9k protein is not
expressed in mutant mice, we expressed the mutant protein in
Escherichia coli, purified it to homogeneity, and produced
antibodies to the mutant calbindin D9k protein. Using this
antibody, no mutant calbindin D9k protein was found in mutant
Fig. 1. Structure of the mutant calbindin D9k gene from ES cell line E14.1.
Exons are underlined; signaling sequences are highlighted.
Fig. 2. Sequence alignment for mutant and wild-type calbindin D9k proteins.
Fig. 3. Western blots of calbindin D9k from wild-type and mutant duodenum
lysates. (A) Results obtained by using antibody to full-length (1–79 aa) calbi-
ndin D9k protein. (B) Results obtained by using antibody to partial (1–60 aa)
calbindin D9k protein. (C) Results obtained by using antibody developed to
mutant calbindin D9k protein (1–100 aa) and using purified recombinant
mutant calbindin D9k (MUT P) as the control.
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mice duodenal lysates, whereas this antibody clearly showed
calbindin D9k in the lysates of wild-type mice (Fig. 3C).
These results clearly demonstrate that putative mutant calbin-
din D9k protein does not exist in the mutant mouse despite the
presence of its mRNA, thus confirming that the mouse that is
homozygous for the mutant calbindin D9k gene is a calbindin D9k
null mouse.
Calbindin D9k Knockout Mice Phenotype and Serum Calcium Level.
The calbindin D9k knockout mice do not exhibit any overt
phenotypic abnormalities: specifically, no skeletal abnormalities
were detected. They grow and develop normally; the growth rate
of the weanlings is comparable to that of the wild type as assessed
by their weekly weight gain. Their life expectancy also does not
differ from the wild type. Calbindin D9k knockout mice retain
similar fertility to the wild-type mice and are fully able to
reproduce. The average size of the litter from the knockout is
comparable to that of wild type as well. To find out whether the
lack of calbindin D9k protein in the knockout mice results in any
effect on calcium homeostasis, serum calcium levels of the
knockout and wild-type mice kept on a chow diet were moni-
tored from 4 weeks of age to adulthood (Fig. 4). The data show
that the serum calcium levels of the knockout and the wild-type
mice are identical over the extended period investigated in both
male and female mice.
Thus, we generated mice lacking the calbindin D9k protein and
demonstrated that knockout mice are indistinguishable from
wild type in phenotype and are able to maintain normal serum
calcium levels in the absence of calbindin D9k protein, regardless
of age or sex. Although a direct assessment of whether the
intestine lacking the calbindin D9k protein can respond to
1,25-dihydroxyvitamin D3 by increasing calcium absorption has
not yet been examined, the fact that serum calcium is normal in
knockout mice suggests that calbindin D9k is not required for
vitamin D-induced calcium absorption. This belief is supported
by the fact that vitamin D receptor null mice are hypocalcemic
under these circumstances (25).
Materials and Methods
Calbindin D9k Gene Insert. P1 clone 7681 with an 85-kb genomic
DNASauIIIA insert containing the calbindin D9k gene from the
mouse E14.1 ES cell P1-ES Library was purchased from Incyte
Genomics.
ES Cell Lines. The ES cell line E14 was derived from the inbred
mouse strain 129OlaHsd in 1985 by Hooper et al. (22). Later,
it was subcloned by Kuhn et al. (21) to become the E14.1 line.
The E14.1B and E14.1C ES cell lines were obtained from Philip
Sanford (Gene Targeted Mouse Service, University of Cincin-
nati, Cincinnati, OH).
Mice. 129OlaHsd mice were purchased from Harlan (Indian-
apolis, IN). Animals were maintained and research was con-
ducted in accordance with guidelines set forth by the Animal
Care and Research Committee of University of Wisconsin.
Identity of the 129Ola Calbindin D9k Gene. The sequence was
established by sequencing the DNA on an LKB ALF DNA
sequencer (GE Healthcare Bio-Sciences, Piscataway, NJ) by
using the Thermo sequenase fluorescent-labeled primer-cycle
sequencing kit (GE Healthcare Bio-Sciences) at the University
of Wisconsin Biotechnology Center DNA SynthesisSequencing
Facility, using the set of 20 primers designed for each direction.
Computer analysis of the sequence was performed with the
Sequence Analysis Software Package from Genetics Computer
Group (Madison, WI).
Generation of Mutant Calbindin D9k Mice. The E14.11C ES cell
subline was injected into C57BL6 host blastocysts at the
University of Wisconsin Biotechnology Center Transgenic An-
imal Facility. ES cells were grown for 3–4 days on a leukemia
inhibitory factor-producing feeder layer. ES cells were disaggre-
gated into a single-cell suspension, separated from the feeder
cells, and injected into the blastocoel cavities of expanded
C57BL6 blastocysts. After the microinjections, the blastocysts
were allowed to recover and transferred into the oviducts of
pseudopregnant recipients. Potential founder pups were born 19
days later, and coat color was identified 1 week later. The
129OlaHsd ES cells were from an agouti strain, and the
blastocysts were from a black strain. Nine males with a high
percentage of agouti hair were produced.
Three founder chimeras were mated to C57BL6 partners at
6–7 weeks of age. All three founders produced agouti pups,
indicating that the injected ES cells contributed to the formation
of the germ line in the founder animals. Agouti F1 pups were
genotyped by PCR.
Chimeric males were bred to 129OlaHsd females (Harlan) to
generate an inbred 129Ola line. All female F1 pups were
heterozygous for the calbindin D9k deletion. The heterozygous
pups were backcrossed to founder males to generate female mice
that were homozygous for the calbindin D9k gene with deletion.
Genotyping of Calbindin D9k Knockout Mice. Genomic DNA was
extracted from mouse tails by using a Puregene DNA isolation
kit (mouse tail kit, Gentra Systems, Minneapolis, MN). To
distinguish the wild-type allele from mutant alleles, a separate
set of primers was designed for each allele. For the wild-type
allele, the downstream primer was designed within the 22-bp
deletion region of exon III of the calbindin gene. Because the
mutant allele lacks this 22-bp region, this primer is unable to bind
to the mutant allele. On the other hand, the downstream primer
for the mutant allele was designed for only the flanking region
Fig. 4. Concentration of Ca2 in the serum of wild-type and calbindin D9k
knockout mice as a function of age and sex. Serum calcium levels in the
wild-type and knockout mice were measured every 4 weeks (see Materials and
Methods). (A) Serum calcium levels in female mice. (B) Serum calcium levels in
male mice.








of the deletion. The sequence of the primer covers part of the left
border and part of the right border of the deletion. Therefore,
the mutant downstream primer was unable to bind to the
wild-type allele for PCR. The upstream primers were also
designed for different regions of the gene upstream. The oligo-
nucleotide primers designed for the wild-type allele were as
follows: upstream, 5-GAT CAT AGT GGG TTT CAG G-3;
downstream, 5-ATC GCC ATT CTT ATC CAG-3. The oli-
gonucleotide primers designed for the mutant allele were as
follows: upstream, 5-CAC CCC ACC GAC CAT CAG-3;
downstream, 5-ATC GCC ATT CTG TCC AGA GT-3. The
size of the wild-type PCR product is 324 bp, and the mutant PCR
product is 189 bp.
Two separate PCRs were run for genomic DNA extracted
from each mouse. One reaction was run with primer sets
designed for wild-type alleles and another reaction was run with
primer sets designed for mutant alleles. PCRs were performed
by using the Advantage cDNA Polymerase Mix from Clontech
Laboratories (Mountain View, CA). The parameters for PCR
were as follows: initial denaturation at 94°C for 4 min followed
by 29 cycles at 94°C for 30 s, 64°C for 40 s, and 72°C for 2 min.
Final extension of the DNA was done for 5 min at 72°C. PCR was
performed by using the Programmable Thermal Cycler PTC 100
(MJ Research, now Global Medical Instrumentation, Ramsey,
MN). The PCR products were visualized on a 1.3% agarose gel
run in 1XTAE after staining with ethidium bromide.
Intestinal Homogenate Preparation for mRNA Isolation. The first 5
cm of intestine (the duodenum) was removed, slit open longi-
tudinally, and scraped with a glass slide to remove mucosa. The
mucosa was homogenized with a PowerGen 700 (Fisher Scien-
tific, Pittsburgh, PA) in guanidine thiocyanate extraction buffer
supplemented with 2% 2-mercaptoethanol (PolyATtract System
1000, Promega, Madison, WI), f lash-frozen in liquid N2, and
stored at 80°C.
mRNA Isolation. Poly(A) RNA was isolated from homogenized
mucosa by using a PolyATtract System 1000 (Promega) and
purified by using an RNeasy kit (Qiagen, Chatsworth, CA). The
quality, integrity, and quantity of the poly(A) RNA were
determined by agarose gel electrophoresis and UV absorption
spectrophotometry.
Reverse Transcription and DNA Amplification by PCR. Reverse tran-
scription of intestinal poly(A) RNA and subsequent DNA
amplification was carried out by using a GeneAmp Gold RNA
PCR reagent kit from Applied Biosystems (Foster City, CA)
according to the conditions recommended by the manufacturer.
The oligonucleotide primers used for DNA amplification were as
follows: sense (upstream), 5-CCT GCT GTT CCT GTC TGA-
3; antisense (downstream), 5-CGT GTC TCC GAA CTT GCT
TTA T-3. The primers were designed to flank the entire coding
region of the mRNA. The RT-PCR was performed on a Pro-
grammable Thermal Cycler PTC 100 (Global Medical Instru-
mentation). After amplification by PCR, the DNA reaction
products were analyzed on 1.4% agarose gel after staining with
ethidium bromide. The sequencing of the PCR product was
carried out with an LKB ALF DNA sequencer (GE Healthcare
Bio-Sciences) by using the Thermo sequenase fluorescent-
labeled primer-cycle sequencing kit (GE Healthcare Bio-
Sciences). Computer analysis of the sequence was performed by
using the Sequence Analysis Software Package from Genetics
Computer Group.
Construction of Plasmid with Mutant Calbindin D9k cDNA Sequence. In
the mutant calbindin D9k cDNA produced by RT-PCR as
described above, restriction sites NdeI and BamHI were incor-
porated into the 5 and 3 sites, respectively. The NdeI site was
located upstream of mutant calbindin D9k cDNA, and the
BamHI site was located right after the stop codon. Using the
generated restriction sites, mutant calbindin D9k cDNA was
subcloned into the expression vector pET-14b (NovagenEMD
Biosciences, Madison, WI). This construct was transfected into
XL-1 Blue Cells (Stratagene). The plasmid with the mutant
calbindin D9k cDNA, p14D9Kmt, was isolated, and the sequence
of mutant calbindin D9k cDNA was confirmed. In this construct,
the mutant calbindin D9k was expressed as protein with the
N-terminal His-tag sequence along with a thrombin cleavage site
that was present between the His-tag and start of mutant
calbindin D9k protein sequence.
Expression of Mutant Calbindin D9k Protein and E. coli Lysate Prepa-
ration. The p14D9Kmt was transfected into BL21-CodonPlus
(DE3)-RIPL Competent Cells (Stratagene) to express the mu-
tant calbindin D9k according to manufacturer’s protocol. Cells
were grown at 37°C, and the expression of the protein was
induced at room temperature by 50  isopropyl -D-
thiogalactoside. E. coli cells were harvested 6 h later and lysed
as follows. Cells (7.7 g) were added to 25 ml of lysis buffer
containing 50 mM TrisHCl (pH 8), 0.5 M NaCl, 20 mM
imidazole, 0.02% sodium azide, 10 mM 2-mercaptoethanol, 20%
glycerol, 1 mM PMSF, 1% Triton X-100, and one Complete,
EDTA-Free Protease Inhibitor Mixture Tablet (Roche Diag-
nostics, Mannheim, Germany). The 2-mercaptoethanol, PMSF,
Complete, EDTA-Free Protease Inhibitor Mixture Tablet, and
Triton X-100 were added to the buffer immediately before
adding the cells. Cells were lysed by sonication while keeping the
lysis mixture cool with an icesalt bath. The lysate was cleared
of cellular debris by centrifugation at 12,851  g at 4°C for 45 min
and then analyzed on 16.5% Tris-Tricine gel.
Purification of Mutant Calbindin D9k. The lysate was poured into a
50-ml conical tube containing 3 ml of NiNTA Superflow (Qiagen)
as a 50% slurry in lysis buffer (see above). The mixture was rocked
for 1 h at 4°C. The slurry was packed into a 1.5-cm-diameter
column, and flow-through was collected. The column was washed
with 10 bed volumes of lysis buffer. The bound protein was eluted
with lysis buffer containing 150 mM imidazole. Protein levels in the
effluent were monitored. A 20-ml volume was collected at the peak
protein concentration and dialyzed two times against 2 liters of 20
mM TrisHCl, pH 8.01 mM EDTA1 mM DTT20% glycerol
0.02% sodium azide. After dialysis, the solution was filtered through
a 0.45-m filter and loaded onto a 2.5  5.7-cm column of
Q-Sepharose (GE Healthcare Bio-Sciences) equilibrated with the
dialysis buffer. We found that the mutant calbindin D9k does not
bind to Q-Sepharose and appears as a single protein in a flow-
through (verified by SDSPAGE), whereas contaminating proteins
do bind to Q-Sepharose and could be eluted with a gradient buffer
(0–500 mM NaCl20 mM TrisHCl, pH 8.01 mM EDTA). After
washing the Q-Sepharose column with dialysis buffer until all
nonbound mutant calbindin D9k was eluted, these fractions were
collected and analyzed on 15% Tris-glycine gel. After SDSPAGE,
the pooled fractions containing pure mutant calbindin D9k (40 ml
total) were brought to a final concentration of 25 mM Ca2 by the
addition of 2.0 M CaCl2, transferred to a 6.4 mlcm 3,500 molecular
weight cutoff SpectraPOR molecular porous membrane tube
(Spectrum Medical Industries, Los Angeles, CA), and concentrated
against PEG 2000 flakes. After 7 h, the sample was dialyzed
overnight in 2 liters of buffer containing 25 mM TrisHCl (pH 8.0),
25 mM CaCl2, 0.02% sodium azide, and 20% glycerol. The protein
was concentrated further by using PEG 2000 flakes and then
dialyzed overnight against a buffer containing 25 mM TrisHCl (pH
8.0), 25 mM CaCl2, 20% glycerol, and 0.02% sodium azide. After
dialysis, the total protein concentration was determined by the
Bradford assay (26).
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Removal of His-Tag from the Purified Mutant Calbindin D9k. His-tag
from the N-terminal site of the mutant calbindin D9k was
removed by using a Thrombin Cleavage Capture kit from
NovagenEMD Biosciences). Removal of the His-tag was ver-
ified by SDSPAGE by using 16.5% Tris-Tricine gel. After
thrombin cleavage, only three extra amino acids (GSH) were left
at the N terminus of the mutant calbindin D9k protein, resulting
in a molecular mass of 11.644 kDa.
Production of Antibody to Mutant Calbindin D9k. Polyclonal anti-
bodies to the mutant calbindin D9k were derived from rabbits and
affinity-purified by Sigma (St. Louis, MO). The antibodies were
tested for their ability to detect the mutant protein by Western
blot analysis.
Intestinal Lysate Preparation for Western Blot. The first 5 cm of the
duodenum was excised from the mouse immediately after carbon
dioxide asphyxiation and immediately washed thoroughly with
ice-cold saline. The duodenum was then homogenized by using a
PowerGen 700 (Fisher Scientific) for 1 min in 1 PBS (pH 7.4)
supplemented with 5 mM PMSF and Complete Mini Protease
Inhibitor Mixture Tablets (one tablet per 7 ml of PBS) from Roche
Diagnostics. One milliliter of PBS was used per 0.28 g of tissue.
The homogenized samples were centrifuged twice for 15 min at
17,382  g. All steps were performed on ice or at 4°C. The total
protein concentration of the lysate (supernatant) was determined
by the method of Bradford (26), using BSA as a standard. The
lysates were aliquoted and stored at 80°C until analysis.
Western Blots. Thirty micrograms of total protein from the
wild-type and mutant mouse duodenum lysates were run on
16.5% Tris-Tricine gel (BioRad Laboratories, Hercules, CA),
and the protein bands were transferred to an Immobilon PSQ
membrane (Millipore, Bedford, MA) by using the TransBlot SD
Semidry System (BioRad Laboratories). The transfer was car-
ried out at 15 V for 31 min. Blots were blocked with 5% nonfat
dry milk solution for 1 h at room temperature. After blocking,
the blots were incubated with a rabbit anti-human calbindin D9k
polyclonal antibody (H-60, sc-28532, 1:100, Santa Cruz Biotech-
nology, Santa Cruz, CA), a rabbit anti-rat recombinant calbindin
D9k polyclonal antibody (1:1,000, SWANT, Bellinzona, Switzer-
land), or a custom-made rabbit anti-mouse mutant calbindin D9k
polyclonal antibody (1:1,000). Finally, blots were incubated with
peroxidase-labeled goat anti-rabbit IgG (1:500,000) from KPL
(Gaithersburg, MD). Immunoreactive protein was detected with
the Immobilon Western Chemiluminescence HRP substrate
from Millipore.
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